Sanofi and Regeneron’s Dupixent shows consistent safety profile

Study involving children aged six to 11 years with moderate-to-severe asthma reveals positive data. Results from a phase 3 extension trial have demonstrated the efficacy and safety profile of Dupixent – also known as dupilumab – as a maintenance therapy when added to other asthma medications.